Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

8 evidence topics · 14 sources

Summary: limitations of cystectomy and of approved bladder-sparing therapies

The EAU guideline states that radical cystectomy is the standard and preferred option for BCG-unresponsive disease and that other treatments must be considered oncologically inferior; it recommends bladder-preserving strategies, preferably within clinical trials, for patients who are not candidates for cystectomy or who decline it. Up to 80% of patients decline or are ineligible for cystectomy. Reported risks of the procedure include morbidity of 50% to 70% and 90-day mortality of approximately 5% (up to 15% in elderly patients), and a manufacturer-funded cost model states that up to one-quarter of patients die and approximately 70% to 80% experience complications within the first year after surgery.

Pembrolizumab, nogapendekin alfa inbakicept-pmln with BCG, and the gemcitabine intravesical system were each approved on the basis of single-arm trials. Their labeled complete response rates were 41% (96 participants), 62% (77 participants), and 82% (83 participants), and no randomized trial compares these agents with each other or with cystectomy. FDA draft guidance states that a randomized controlled trial is preferable and can provide stronger evidence of effectiveness, that time-to-event endpoints are uninterpretable in a single-arm trial, and that a single-arm study cannot assess the contribution of each drug in a combination. For papillary-only disease resected at or before trial entry, the FDA recommends a randomized controlled trial with a time-to-event endpoint. In October 2026, the FDA extended the nogapendekin alfa inbakicept-pmln indication to papillary-only disease by extrapolation from efficacy in disease containing CIS. Labeling for pembrolizumab and the gemcitabine intravesical system is limited to disease with CIS, and pembrolizumab is further limited to patients ineligible for or electing not to undergo cystectomy. Of 31 BCG-unresponsive trials registered on ClinicalTrials.gov, 15 (48%) had enrollment criteria fully consistent with the FDA definition, which the authors state hinders comparisons across agents.

In a meta-analysis of bladder-sparing trials after BCG failure cited by the EAU guideline, pooled 12-month response rates were 24% for trials with more than 2 prior BCG courses and 36% for those with more than 1, and initial response did not predict durable response. Among responders, 46% (pembrolizumab), 58% (nogapendekin alfa inbakicept-pmln with BCG), and 51% (gemcitabine intravesical system) had a duration of response of at least 12 months in the labels. In QUILT-3.032 Cohort A, complete response rates at the 12-, 24-, and 36-month assessments were 47%, 30%, and 16% of 100 participants; in SunRISe-1 Cohort 2, the complete response rate 12 months after treatment initiation was 45.9%. The QUILT-3.032 median duration of response was considered an unreliable estimate because of the limited sample size, small number of events, and substantial censoring. Progression to muscle-invasive disease occurred in 10% (8 participants) in QUILT-3.032 and 8% (7 of 83 evaluable participants) in SunRISe-1 Cohort 2, and each label warns that delaying cystectomy can lead to muscle-invasive or metastatic disease.

Nogapendekin alfa inbakicept-pmln is given with BCG, and TICE BCG is the only approved BCG strain marketed in the U.S. Merck, its sole U.S. manufacturer since 2012, allocates supply to wholesalers and distributors by historical purchasing patterns; in its 2026 letter to health care professionals it reported delays to full startup of a new facility and stated that it will provide an update on timing in the first quarter of 2027. In Medicare claims, BCG use for initial induction therapy decreased from 38.9% before the shortage to 33.0% during it.

Cystectomy refusal, ineligibility, and perioperative risk
Single-arm trial evidence and FDA trial design recommendations
Durability of complete response
BCG supply constraints